By Researchers from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences recently published in Molecular & Cellular Proteomics, describing their work in identifying key metabolic regulators involved in cancer cell resistance to gemcitabine (Gem), a standard-of-care chemotherapy for pancreatic dual adenocarcinoma (PDAC), the most lethal type of pancreatic cancer.
Researchers identify key metabolic regulators of drug resistance in the fight against pancreatic cancer
Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk
Comments